Comparative single-cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses

Seungbyn Baek; Junha Cha; Min Hee Hong; Gamin Kim; Yoon Woo Koh; Dahee Kim; Wonrak Son; Chan-Young Ock; Seungeun Lee; Martin Hemberg; Seong Yong Park; Hye Ryun Kim; Insuk Lee

doi:10.1002/cac2.70046

Cancer Communications ›› 2025, Vol. 45 ›› Issue (9) : 1194 -1199. DOI: 10.1002/cac2.70046

LETTER TO THE JOURNAL

Comparative single-cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses

Author information +

History +

PDF

Cite this article

Download citation ▾

Seungbyn Baek, Junha Cha, Min Hee Hong, Gamin Kim, Yoon Woo Koh, Dahee Kim, Wonrak Son, Chan-Young Ock, Seungeun Lee, Martin Hemberg, Seong Yong Park, Hye Ryun Kim, Insuk Lee. Comparative single-cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses. Cancer Communications, 2025, 45(9): 1194-1199 DOI:10.1002/cac2.70046

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Network CGAR. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017; 541(7636): 169.

[2]	Sun J-M, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. The Lancet. 2021; 398(10302): 759-71.

[3]	Shoji Y, Koyanagi K, Kanamori K, Tajima K, Ogimi M, Ninomiya Y, et al. Immunotherapy for esophageal cancer: where are we now and where can we go. World Journal of Gastroenterology. 2024; 30(19): 2496.

[4]	Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, et al. Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer discovery. 2022; 12(3): 670-91.

[5]	Croft W, Evans RP, Pearce H, Elshafie M, Griffiths EA, Moss P. The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy. Molecular Cancer. 2022; 21(1): 200.

[6]	Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, et al. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nature Medicine. 2023: 1-13.

[7]	Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms. Cancer gene therapy. 2021; 28(1-2): 5-17.

[8]	Ukita M, Hamanishi J, Yoshitomi H, Yamanoi K, Takamatsu S, Ueda A, et al. CXCL13-producing CD4⁺ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI insight. 2022; 7(12): e157215.

[9]	Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J, et al. Hypoxia as a driver of resistance to immunotherapy. Drug Resistance Updates. 2021; 59: 100787.

[10]	Ji G, Yang Q, Wang S, Yan X, Ou Q, Gong L, et al. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma. Genome Medicine. 2024; 16(1): 49.